Asbestos-the Silent Killer: a review of screening and diagnostic imaging of asbestos related lung disease


Submitted: 29 June 2011
Accepted: 8 September 2011
Published: 12 September 2011
Abstract Views: 1651
PDF: 1458
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Ali Nawaz Khan North Manchester General Hospital, Pennine Acute NHS Trust, Manchester, United Kingdom.
  • Hamdan Al-Jahdali King Saud University for Health Sciences, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
  • Klaus L. Irion The Cardiothoracic Centre Liverpool NHS Trust, The Royal Liverpool University Hospital, United Kingdom.
  • Shyam Sunder Koteyar North Manchester General Hospital, Pennine Acute NHS Trust, Manchester, United Kingdom.
An epidemic of asbestos related lung (ARLD) disease stares the developed countries in the face. However, these countries have lately banned the use of asbestos. Nevertheless, Western countries have no qualms of selling asbestos to poor countries that have no credible health safety regulations in the work place. Epidemiologic studies predicted a decline in incidence of ARLD in the US after the year 2000, with a peak incidence in the UK in 2020. Lung cancer (LC) develops in up to 25% of asbestos workers. In exposed nonsmokers, there is 5-fold increase. In exposed individuals, smoking further increases the risk of bronchogenic carcinoma by 80-90-fold. However the silent killer, asbestos is still active in developing countries and is likely to remains so in decades to come. In the Middle East, immigrant workers still work in asbestos environment. Saudi Arabia is the only major country in the Middle East that has banned asbestos, but workers continue to be at risk due to maintenance work on buildings built before the ban. As asbestos related lung disease remains silent in many and has a long latent period, the only way of detecting these diseases early is by diligence being aware of the patient’s occupational history and affective imaging. Presently there is no credible screening for ARLD. Here we review imaging studies in ARLD to increase awareness of this potentially lethal disease. Whereas diagnosis of ARLD is a matter for compensation in the developed countries it is a matter of survival in the developing world where industrialization has just begun and may take decades to remove the threat of asbestos. In this review we will discuss the clinical, radiologic, and pathologic features of ARLD.

Hamdan Al-Jahdali, King Saud University for Health Sciences, King Abdulaziz Medical City, Riyadh

Supporting Agencies

none

Khan, A. N., Al-Jahdali, H., Irion, K. L., & Koteyar, S. S. (2011). Asbestos-the Silent Killer: a review of screening and diagnostic imaging of asbestos related lung disease. Chest Disease Reports, 1(1), e13. https://doi.org/10.4081/cdr.1.111

Downloads

Download data is not yet available.

Citations